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Abstract
Growing evidence points to synaptic pathology as a core component of the pathophysiology of 
schizophrenia (SZ). Significant reductions of dendritic spine density and altered expression of 
their structural and molecular components have been reported in several brain regions, suggesting 
a deficit of synaptic plasticity. Regulation of synaptic plasticity is a complex process, one that 
requires not only interactions between pre- and post-synaptic terminals, but also glial cells and the 
extracellular matrix (ECM). Together, these elements are referred to as the ‘tetrapartite synapse’, 
an emerging concept supported by accumulating evidence for a role of glial cells and the 
extracellular matrix in regulating structural and functional aspects of synaptic plasticity. In 
particular, chondroitin sulfate proteoglycans (CSPGs), one of the main components of the ECM, 
have been shown to be synthesized predominantly by glial cells, to form organized perisynaptic 
aggregates known as perineuronal nets (PNNs), and to modulate synaptic signaling and plasticity 
during postnatal development and adulthood. Notably, recent findings from our group and others 
have shown marked CSPG abnormalities in several brain regions of people with SZ. These 
abnormalities were found to affect specialized ECM structures, including PNNs, as well as glial 
cells expressing the corresponding CSPGs. The purpose of this review is to bring forth the 
hypothesis that synaptic pathology in SZ arises from a disruption of the interactions between 
elements of the tetrapartite synapse.
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1. Introduction
Growing evidence points to synaptic pathology across several brain disorders, including 
schizophrenia (SZ), bipolar disorder, major depression, autism spectrum disorder and 
Alzheimer’s disease. Research on the underlying mechanisms for this pathology has only 
very recently begun to make headway, and important questions arise with regard to the 
potential common denominators of synaptic pathology among these disorders, and their 
timeframe across lifespan. With regard to the latter, it is important to consider that synaptic 
remodeling occurs constantly throughout life. During postnatal development, excessive 
synaptic formation is followed by elimination of less active synapses, a process named 
synapse pruning [1, 2]. During adult life, synapses are highly dynamic, with constant, 
experience-driven synaptic growth and elimination. It is plausible to postulate that 
timeframe-, mechanism- and brain region- specificity underlying synaptic pathology across 
a spectrum of brain disorders may at least in part contribute to their diverse clinical and 
pathophysiological manifestations. Within this context, we suggest that the concept of 
‘tetrapartite synapse’ may be a useful starting point for investigating synaptic pathology. We 
focus on schizophrenia as a notable example.
1.1. The tetrapartite synapse
The chemical synapse has classically been considered as composed of two main elements, 
i.e. the presynaptic and postsynaptic elements. This concept evolved over the past two 
decades to include a third element, i.e. the astrocyte, as processes from these cells envelope 
the synapse and play a key role in regulating its functions [3,4]. The ensemble of pre- and 
postsynaptic elements and astrocytes has been proposed to form a functional complex 
referred to as the ‘tripartite synapse’ [5]. Growing evidence indicates that other populations 
of glial cells, including NG2 glia and microglia, also play critical roles in regulating synaptic 
functions and plasticity. Thus, we suggest that distinct populations of glial cells with specific 
functions may be considered together to represent the third element of tripartite synapse. Yet 
more recently, the extracellular matrix (ECM) has come to the forefront of neuroscience as 
an active component of neural functions and, in particular, synaptic regulation. On the basis 
of this evidence, Dityatev et al., proposed the elegant concept of the ‘tetrapartite synapse’, 
composed of pre- and post-synaptic elements, glial processes and ECM, and elegantly 
documented the interactions between these components [6–8] (Fig. 1). Here, we review 
evidence supporting the idea that synaptic functions and plasticity result from interactions 
between all elements of the tetrapartite synapse, and focus on evidence that these 
interactions are disrupted in SZ.
1.1.1. The tetrapartite synapse: pre- and post-synaptic elements—The brain 
possesses the extraordinary ability to continuously reshape itself throughout the entire 
lifespan. This property, defined as plasticity, is based on the highly dynamic properties of 
synaptic contacts, i.e. the ability to generate new synapses, eliminate them, and alter the 
electrophysiological, molecular and structural properties of existing ones in response to 
experience. The mechanisms underlying synaptic plasticity have been the object of intense 
work and exciting discoveries over the past few decades, focused initially on the interplay 
between the presynaptic and postsynaptic elements. For example, the discovery that trains of 
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presynapticaction potentials induce a long-lasting increase in synaptic strength during long 
term potentiation (LTP) generated intense debate over whether the predominant underlying 
changes may be related to postsynaptic modification in α-amino-3-hydroxy-5-methyl-4-
isoxazolepro-pionic acid receptors (AMPARs) or altered presynaptic transmitter release 
[9,10]. Ensuing work demonstrated that these mechanisms include a series of steps, from 
receptor phosphorylation, to protein synthesis and, eventually, structural changes including 
growth of new dendritic spines and increased size of pre-existing spines, mediated by 
changes dendritic spine molecular cytoskeleton, including long-lasting increases in F-actin 
content within spines and condensation of the post-synaptic density (PSD), a dense 
aggregate of scaffolding proteins implicated in structural maintenance and signal 
transduction [11–13]. Similarly, long-term depression (LTD) of synaptic strength results in 
spine shrinkage and elimination [14–17]. A review of current knowledge on the role of pre-
and post-synaptic elements in plasticity is beyond the scope of this manuscript; arguably 
plastic modifications of these elements may be considered to be the final result of complex, 
experience-driven mechanisms, and the underlying substrate of learning and memory.
1.1.2. The tetrapartite synapse: role of glial cells
1.1.2.1. Astrocytes: Astrocytic processes envelop the pre- and postsynaptic elements and 
closely approach the synaptic cleft, thus representing a key component of the synapse [3,18] 
(Fig. 1). Their robust expression of the high-affinity glutamate transporters EAAT1-EAAT2 
allows them to rapidly re-uptake excess of glutamate released from the presynaptic 
terminals, thus restricting excitatory transmission [19]. In turn, astrocytes actively contribute 
to synaptic transmission and plasticity. Although electrically silent, they respond to 
presynaptic activation with G-protein-mediated Ca2 signals, triggering the release of 
‘gliotransmitters’, including glutamate, ATP, and GABA, which modulate local synaptic 
transmission [20–25]. Astrocyte-derived glutamate facilitates NMDA receptor activation on 
the postsynaptic sites, enhancing the probability of triggering LTP [26]. Moreover, stimuli 
inducing synaptic LTP rapidly induce structural remodeling of astrocytic processes 
enwrapping synapses, resulting in changes in their ability to modulate synaptic transmission 
[27]. Together, these considerations compellingly point to astrocytes as key active mediators 
of synaptic plasticity.
1.1.2.2. NG2 cells: In the early nineties, a novel population of cells was identified by their 
expression of the CSP GNG2, platelet-derived growth factor α receptors (PDGFαR), and O4 
sulfatide (O4) [28–30]. These cells are abundant in the white and gray matter, and have been 
shown to represent the main source of mature oligodendrocytes in the mature brain, earning 
the name of oligodendrocyte precursor cells [31]. However, morphological features of NG2 
cells closely resemble those of mature astrocytes, while their molecular signature is quite 
distinct [29,32,33]. Further studies showed that NG2 cells represent a distinct matureglial 
type with unique properties. Indeed, a growing body of evidence indicates that NG2 cell 
express voltage-gated ion channels and ligand-gated ionotropic neurotransmitter receptors, 
typically found in neurons but not in glial cells; this peculiar pattern of molecular expression 
endows them with a unique electrophysiological profile [34]. They are the only glial cell 
type capable of receiving synaptic GABAergic and glutamatergic contacts from neurons, and 
to respond to excitatory inputs with excitatory postsynaptic currents and activity-dependent 
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modifications analogous to LTP at excitatory synapses, although with some notable 
differences [35–37]. Electron microscopy studies demonstrated that NG2 cell processes 
often encapsulate neuronal cell bodies and contact synapses [38]. Potential effects of NG2 
cells on synaptic transmission are suggested by experiments showing that downregulation of 
NG2 expression results in altered subunit composition of AMPA receptors and marked 
reduction of NMDA-dependent LTP [39]. The full range of NG2 cell functions is only 
partially understood, and is likely to be age-, stage- and brain region-specific; however, 
plastic responses of these cells to excitatory neurotransmission and their intimate contacts 
with synaptic complexes strongly suggest that they play a significant role in the regulation of 
synaptic functions and plasticity [34,40–43].
1.1.2.3 Microglia: Microglial cells serve diverse roles during brain development and 
adulthood, from regulation of synaptic pruning and plasticity to removal of apoptotic cells 
and debris, and immune responses, representing primary sources of immune response factors 
such as cytokines (see 44). Notably, these seemingly unrelated functions may in fact share 
similar mechanisms, as growing evidence indicates that immune factors play important roles 
in the regulation of synaptic plasticity [45]. Microglial cells express an impressive variety of 
receptors, including not only immune receptors, such as pattern-recognition receptors that 
allow them to recognize pathogen-associated molecular patterns and tissue damage–
associated molecular patterns and chemokine receptors, but also a surprisingly large number 
of receptors for neurotransmitters and neuropeptides [44]. These two latter categories 
include ionotropic and metabotropic glutamate receptors, and receptors for GABA, 
dopamine, catecholamines and acetylcholine, which mediate neural-glia communications. 
These receptors modulate the release of cytokines and guide microglial processes toward 
active synapses, where they regulate synaptic structural plasticity [44–46]. In particular, 
microglia represent a key player in the remodeling, particularly removal, of inactive 
synapses during brain development and adulthood. Microglia processes are highly dynamic, 
continually extending, retracting and interacting with synapses, thus as acting like sentinels 
to assess surrounding synapses and contribute to their remodeling when needed [20–23]. 
Among the immune-related molecules involved in these mechanisms are several 
complement factors, which act as signal to microglia to find and engulf pre and post-
synaptic elements [47–49]. Complement signaling pathways also mediate microglia-induced 
long term depression (LTD), involved in brain circuitry optimization, and potentially in 
memory impairments and synaptic disruptions in neuroinflammation-related brain disorders 
[50]. Notably, the strongest genetic association observed in SZ involves variation in the 
Major Histocompatibility Complex locus, shown to arise predominantly from alleles of the 
complement component 4 (C4) genes [51,52]. Elegant work by Sekar et al. recently showed 
that these alleles do affect C4 expression and that this factor mediates synapse elimination 
during postnatal development [52]. In summary, microglial cells play a key role in shaping 
synaptic connectivity in an activity-dependent manner – the underlying mechanisms involve 
molecular factors with strong relevant to the pathophysiology of SZ.
1.1.3. The tetrapartite synapse: role of the extracellular matrix—The brain ECM 
is a complex molecular network that surrounds all cells, occupying approximately a 20% 
volume fraction of the adult brain [53]. It’s main components include hyaluronan, 
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proteoglycans, glycoproteins and a variety of posttranslational remodeling proteases, such as 
matrix metalloproinases (MMPs), ‘a disintegrin and matrix metalloproteases’ (ADAMS), 
and ‘ADAMS with a thrombospondin domain’ (ADAMTS), which cleave ECM molecules, 
allowing for highly dynamic functional adaptations [54–58]. As discussed below, organized 
forms of ECM surround the synapse, fill the synaptic cleft and interact with cell surface 
receptors (Fig. 1). Converging evidence points to peri-synaptic ECM aggregates as a critical 
player contributing to synaptic signaling and plasticity.
1.1.3.1. ECM factors regulating synaptic plasticity: Chondroitin sulfate proteoglycans 
(CSPGs) have been described as the organizers of the ECM, of which they represent a main 
component [59–64]. These macromolecules consist of core proteins linked to varying 
numbers of chondroitin sulfate (CS) glycosaminoglycan (GAG) chains. The number and 
length of GAG chains, and particularly their sulfation patterns (e.g. CS-6, CS-4), are key 
factors in determining their functions, resulting in highly dynamic structural and functional 
diversity to these molecules [65–68]. While their functions in the developing and mature 
brain are highly diversified, mounting evidence indicates that CSPGs play a complex role in 
developmental and adult regulation of synaptic plasticity. For example, enzymatic CSPG 
removal in vitro mouse hippocampal slices causes a two-fold decrease in long-term 
potentiation (LTP) [69]. Overexpression of CS-6 sulfation in mice leads to failure to instate 
an adult form of restricted plasticity [66]. Altered expression of several CSPGs, such as 
PTPRZ1, neurocan and brevican, was found to be associated with synaptic remodeling LTP 
abnormalities and learning impairment [70–75]. Notably, several CSPGs have been shown to 
actively stabilize dendritic spines, while their removal by enzymatic digestion results in 
increased spine motility [76–79].
Several other ECM molecules have been found to be involved in the regulation of synaptic 
plasticity. For instance, genetic or pharmacological removal of the ECM component 
tenascin-C and thrombospondins 1 and 2 resulted in reduced calcium signaling and impaired 
LTP in rodents (Evers et al.; Dityatev et al.). Hyaluronan, considered to be the backbone of 
the ECM and enriched in PNNs and other forms of ECM perisynaptic aggregates, was found 
to regulate hippocampal synaptic plasticity by modulating postsynaptic L-type Ca2+ 
channels [80]. Other ECM components have been shown to modulate chemical transmission 
by acting on glutamate NMDA and AMPA receptors and impacting adaptive synapse 
modifications. Particularly relevant to several brain disorders, including SZ, is the ECM 
glycoprotein Reelin. Reelin’s effects are mediated through its main lipoprotein receptors, 
apolipoprotein E receptor 2 and very-low-density lipoprotein receptor [81,82], as well as 
through the integrin family and the Src family kinases [82–85]. Reelin is secreted into the 
ECM, where it regulates the composition of NMDA receptors, controlling the predominance 
and/or phosphorylation of the NR2 NMDA receptor subunits, augments AMPA responses by 
increasing the number of AMPA receptors on the postsynaptic membrane, and robustly 
enhances LTP [85–87]. Reelin powerfully promotes spine remodeling, regulating spine size 
and stability, and number of synaptic contacts per spine [88–93]. Integrins, known to interact 
with Reelin and other ECM molecules, regulate AMPA receptor internalization, surface 
mobility of NMDA receptor subunits, and synaptic dwell time of glycine receptors and their 
scaffolding molecule gephyrin [94–97]. These mechanisms have been postulated to allow 
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integrins to play complex roles in synaptic plasticity, including carrying out structural and 
functional changes that accompany LTP [97–99]. Secreted ECM proteases, such as MMPs, 
affect excitatory transmission and have extensively been investigated as mediators of 
synaptic plasticity [100–103]. During development, MMPs play a key role in spine 
formation and maturation [104–106]. In mature neurons, MMPs and their interactions with 
integrins, are required for spine volume changes induced by LTP and LTD [107,108]. 
MMP-9 is transiently released in response to enhanced neuronal activity and impacts both 
synaptic potentiation and dendritic spine enlargement in a dependent manner [108,109]. 
Notably, several MMPs have been shown to be represented in WFA-labeled PNNs [110], 
suggesting a role in regulating their functions. Semaphorins, key components of the ECM, 
have also been shown to regulate synaptogenesis (Pasterkamp & Giger 2009). For instance, 
semaphorin 3A, a key component of at least a subpopulation of PNNs, exerts a powerful 
effect on synapses, possibly through its plexin and neuropilin receptors [106,111–114].
1.1.3.2. ECM perisynaptic aggregates
1.1.3.2.1. Perineuronal nets: In addition to a loosely organized molecular lattice, the ECM 
forms organized, structured aggregates with distinct molecular composition. PNNs are 
arguably the most extensively investigated. They tightly surround synaptic contacts on 
distinct populations of neurons, including GABAergic interneuron populations and 
GABAergic projection neurons, such as those in the reticular nucleus of the thalamus, 
central nucleus of the amygdala and Purkinje cells in the cerebellum, as well as 
subpopulations of cortico-cortical pyramidal cells and spinal cord motor neurons [62,115–
121]. PNNs represent key players in the regulation of synaptic connectivity and plasticity 
[111,122–129]. They mature late in postnatal development, in an activity-dependent manner 
[130–133]. Their maturation brings to a closure critical periods of development, inducing a 
profound shift from juvenile forms of plasticity to more restricted mature forms, 
consolidating successfully established synaptic connectivity and controlling formation of 
new synapses [76,124,129,134]. Enzymatic CSPG digestion dramatically disrupts PNN 
integrity, reverting local circuits and learning modalities, from visual perception to 
emotional learning, to a juvenile state [129,134]. The molecular composition of mature 
PNNs is thought to be species-, neuron- and brain region-specific, but to include CSPGs, 
hyaluronan and a variety of glycoproteins described above in relationship to synaptic 
plasticity regulation. Thus, functions such as modulation of glutamatergic transmission, LTP 
and LTD and synaptic motility and structural plasticity, demonstrated for these molecules, 
are inherent to PNNs. In addition, recent evidence shows that PNNs are in themselves 
dynamically regulated [123]. Fear learning and consolidation in response to pure tones was 
shown to induce marked PNN changes in the adult auditory cortex [123]. Expression CSPG 
mRNA and numbers of PNN were increased within hours following fear conditioning and 
returned to baseline 24 h later. CSPG enzymatic digestion in the auditory cortex impaired 
fear learning and consolidation, demonstrating that PNNs are necessary for fear learning 
[123]. Notably, in the amygdala, CSPG digestion also affected fear learning, reinstating 
juvenile forms of extinction-vulnerable conditioning [129].
1.1.3.2.2. CS-6/Glia clusters: Contrary to what initially thought, PNNs are not unique as 
forms of organized ECM in the brain. Among other forms, CS-6/Glia clusters, or 
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DAndelion-like Clock Structure, may be equally relevant to synaptic plasticity [135,136]. 
CS-6/Glia clusters are detectable in human and rodent brain using antibodies raised against 
the CS-6 sulfation patterns (Fig. 2). Their morphology may vary across brain regions, but in 
general they present as round rosettes of diffuse immunolabeling, with an overall diameter 
of 100–200 µm, often organized in short, dense segments. Several dendrites, and 
occasionally some neuronal and glial cell bodies are embedded in these clusters, while 
several glial cells surround them (Chelini et al; unpublished observations) [135,137]. In the 
mouse brain, CS-6/Glia clusters were found to develop in late postnatal development, 
suggesting a role in regulation of synaptic connectivity similar to that shown for PNNs 
[135,137–141]. Increases of CS-6 clusters in response to ketamine treatment suggest that 
these structures may be responsive to changes of glutamatergic transmission [142]. Although 
still preliminary, information on CS-6/Glia clusters is consistent with their involvement in 
synaptic functions, potentially representing segregated microenvironments regulated by 
predominant expression of CS-6 sulfation. The functional effects of these sulfation patterns 
are currently poorly understood, but evidence suggests a role for CS-6 sulfation patterns in 
facilitating plasticity. A switch from CS-6 to CS-4 sulfation patterns during postnatal 
development, and persistent cortical plasticity induced by CS-6 upregulation, suggest that 
the former may be more permissive, facilitating plasticity, while CS-4 may represent the 
mature, less permissive, CSPG form [66] (Fig. 3).
1.2. Synaptic pathology in SZ
Growing evidence overwhelmingly points to synaptic abnormalities as core component of 
the pathology of SZ. Significant reductions of dendritic spines have been reported in several 
cortical areas, including prefrontal and auditory cortical areas and the hippocampus [143–
147]. Anomalous dendritic spine morphology, expression of PSD proteins, including PSD95 
and Homer-1, and associated glutamate signaling pathway proteins have also been reported 
[148,149]. Altered expression of molecules involved in the actin cytoskeleton strongly 
suggests that dendritic spines in SZ may reflect structural deficits [150–152]. A recent study 
shows dramatic changes affecting genes involved in synaptic functions in the amygdala 
[153], notably one of the main regions shown to have significant ECM abnormalities in this 
disorder. Decreases of dendritic spines in SZ have been proposed to represent the 
consequence of overpruning during adolescence [154,155].This hypothesis predicts a loss of 
large, mature spines in this disorder. Contrary to this expectation, a recent report shows that, 
at least in the primary auditory cortex, loss of dendritic spines in SZ may predominantly 
reflect decreases of smaller spines, and potentially be related to the SZ risk gene CACNB4 
[154]. These findings are prompting novel hypotheses on the potential causes of synaptic 
pathology in SZ, and its links to genetic vulnerabilities. Importantly, GWAS data and de 
novo CNV analyses strongly support the involvement of genes involved in synaptic 
plasticity, and specifically, encoding for elements of the postsynaptic density, as risk factors 
for SZ [51,156]. Among these are alleles of the complement component 4 (C4) genes which, 
as mentioned above, were recently shown to play a key role in synapse elimination during 
postnatal development [51,52]. Additional genetic loci associated with genetic vulnerability 
to SZ also include genes encoding for ECM molecules and particularly ECM remodeling 
proteases [51]. Together, these studies support the possibility that risk genes affecting 
synaptic functions and ECM may interact with each other and with secondary or 
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environmental factors to affect elements of the tetrapartite synapse, ultimately resulting in 
disruption of synaptic functions and plasticity.
2. Methods
Methods briefly described here refer to investigations on postmortem human tissue carried 
out by our group.
2.1. Human subjects
Tissue blocks containing the regions of interest (e.g. the amygdala) from cohorts of normal 
control and SZ donors (n = 12–25/group) were used for histochemical, immunocytochemical 
and qRT-PCR studies. All tissue blocks were obtained from the Harvard Brain Tissue 
Resource Center (HBTRC), McLean Hospital, Belmont, MA, USA. Diagnoses of SZ and 
BD were made by two psychiatrists on the basis of retrospective review of medical records, 
extensive questionnaires concerning social and medical history provided by family members 
and neuropathological report. Cohorts did not include subjects with evidence for gross 
and/or macroscopic brain changes, or clinical history, consistent with cerebrovascular 
accident or other neurological disorders. Subjects with Braak stages III or higher [157] 
(modified Bielschowsky stain) were not included.
2.2. Tissue processing and data collection
Tissue blocks were dissected from fresh brains, lightly fixed and cryoprotected (for 
immunohystochemistry (IHC) only), or quickly frozen in liquid nitrogen vapor (for Western 
blotting and qRT-PCR), then sectioned using a freezing microtome or a cryostat. Specificity 
of primary antibodies for IHC was tested by immunoblotting and pre-absorption with the 
corresponding antigen. WFA, and a variety of antibodies raised against CSPG protein cores 
(e.g. aggrecan), or CSPG CS-6 sulfation patterns (CS56, 3B3) were used to label PNNs and 
CS-6 clusters. Procedures for protein and mRNA detection and data collection were carried 
out as reported previously [e.g. 136,158].
2.3. Statistical analysis
Differences between groups relative to the main outcome measures in each of the regions 
examined were assessed for statistical significance using an ANCOVA stepwise linear 
regression process. Effect sizes were calculated according Hedges’ g. A logarithmic 
transformation was uniformly applied to all original values because the data were not 
normally distributed. Age, gender, postmortem time interval, inflammation (classified as 
positive or negative for inflammatory condition at time of death), hemisphere, cause of 
death, brain weight, exposure to alcohol, nicotine, electroconvulsive therapy, and lifetime, as 
well as final six months’, exposure to antipsychotic drugs, exposure to selective serotonin 
reuptake inhibitors classified as positive or negative for exposure, and lithium treatment 
were tested systematically for their effects on the main outcome measures, and included in 
the model if they significantly improved the model goodness of-fit (see also 136,158]
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3. Results
3.1. ECM pathology in SZ
Human postmortem studies from our group consistently show marked decreases of PNNs in 
people with SZ [136,138,158–160]. Our first findings showed significant reduction of PNNs 
labeled with the lectin Wisteria floribunda agglutinin (WFA) in the amygdala and entorhinal 
cortex of subjects with SZ [158]. Similar decreases of WFA-labeled PNNs were also 
detected in the prefrontal cortex and hippocampus, but not in the visual cortex, consistent 
with specific involvement of brain regions impacted in SZ [138,159]. Notably, numbers of 
neurons predominantly associated with WFA-labeled PNNs, i.e. interneurons expressing 
parvalbumin [161–164], were not decreased in these regions [165–169]. This latter finding 
supports the idea that PNN decreases do not depend on a corresponding reduction of the 
neurons they envelope, while at the same time suggest that they may contribute to functional 
abnormalities affecting these neurons in SZ [169,170]. WFA labels a distal N-
acetylgalactosamine on the CS chains of a group of CSPGs. Thus, decreases of WFA-
labeled PNNs suggest CSPG involvement in SZ. To test the hypothesis that PNN decreases 
in SZ may not be restricted to WFA-positive PNNs, we focused on aggrecan, one of the 
main CSPGs in the brain and a major component of a population of PNNs, and on CS-6 
sulfation patterns. Our results showed marked decreases of PNNs containing aggrecan and 
CS-6 sulfation in the amygdala of people with SZ [136]. Decreases of aggrecan-positive and 
WFA-positive PNNs were detected exclusively in the lateral nucleus of the amygdala; 
however, only one-third of WFA-positive PNNs also expressed aggrecan, raising the 
possibility that neuronal populations affected by WFA- and aggrecan-positive PNN loss only 
partially overlap. Decreases of CS-6 immunoreactive PNNs were much broader, impacting 
several amygdala nuclei, including the lateral, basal, accessory basal, cortical, and medial 
nuclei. Together, these findings show that PNN abnormalities in the amygdala of people with 
SZ include several distinct PNN phenotypes encompassing multiple neuronal populations. 
Such heterogeneity in PNN phenotypes is consistent with previous findings in several other 
brain regions [171–173].
Results from these postmortem studies also show complex interactions between PNN 
decreases and glial cells abnormalities. In the amygdala and entorhinal cortex, WFA-positive 
PNN decreases were accompanied by a robust increase of WFA-positive astrocytes affecting 
all amygdala nuclei and entorhinal cortex subregions tested, in contrast to the more restricted 
PNN changes. We speculate that impaired CSPG secretion in glial cells may be causally 
linked to WFA-positive PNN decreases. In contrast to results with WFA, aggrecan-positive 
PNN decreases were accompanied by marked reductions of glial cells expressing this CSPG 
[136], suggesting decreased aggrecan supply from glial cells. Together, these findings are 
consistent with the hypothesis that interactions between glial cells and ECM may be 
disrupted in SZ. This hypothesis is also supported by our findings that CS-6/Glia clusters, 
labeled with two different CS-6 antibodies (CS56 and 3B3), are markedly decreased in the 
amygdala of SZ [136]. As mentioned above, CS-6/Glia clusters putatively represent a novel 
form of structured ECM, postulated to affect dendritic spines. Their decreases may represent 
a clear example of disruption of the interactions between elements of the tetrapartite 
synapse, i.e. glial cells, ECM and pre- and post-synaptic elements. Additional evidence for 
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the involvement of the ECM in SZ comes from findings in the olfactory epithelium, a 
peripheral sensory organ where neurogenesis and axon growth occur throughout adult life 
[174–176]. ECM components, and CSPGs in particular, are suspected to play a key role in 
these functions. Postmortem findings from our group show that cytoplasmic CSPG 
expression is altered in olfactory receptor neurons, potentially contributing to a disruption of 
olfactory functions observed in people with SZ [177–185].
4. Discussion
In summary, our findings show consistent ECM abnormalities in people with SZ, including 
reductions of PNNs, altered CSPG expression in glial cells and reduced numbers of CS-6/
Glia clusters. These abnormalities are large in magnitude, robust to confounding factors and 
shared by several brain regions involved in SZ {[136] Pantazopoulos #1181; [138] Mauney 
#7280; [158] Pantazopoulos #17815}. Yet, they are restricted in their distribution to specific 
cortical layers and amygdala nuclei, suggesting specialized mechanisms affecting distinct 
neuronal populations.
The causative mechanisms underlying ECM abnormalities are not yet well understood. 
However, support for the contribution of genetic factors can be found in a growing number 
of studies. A common variation of NCAN, encoding neurocan, a brain-specific CSPG highly 
represented in the brain, has been reported and replicated in several studies, including a large 
GWAS with more than 36000 SZ cases [51,186,187]. This latter study also discovered SZ 
risk factors from several other ECM molecules, including MMP-16 [51]. Several additional 
studies reported the involvement of other MMPs, of which MMP-9 may be the most notable. 
For instance, polymorphisms of MMP-9 have been shown to be associated with SZ, 
although some negative findings have also been reported, and plasma levels of MMP-9 were 
found to be altered in this disorder [109,188–190]. Together, these findings led to 
suggestions that MMPs may represent a novel therapeutic target for SZ [190,191]. Notably, 
dose-dependent MMP-9 activity is crucially modulated by mir-132, a microRNA identified 
as pivotal for synaptic plasticity and found to be decreased in blood and brain tissue of 
people with SZ [192–195]. Together, these findings support the hypothesis of aberrant 
CSPGs processing during activity dependent plasticity, potentially linking CSPGs 
abnormalities to synaptic pathology in SZ.
4.1. The tetrapartite synapse: role in synaptic pathology in SZ
Converging evidence reviewed here and elsewhere compellingly support the idea that all 
elements of the tetrapartite synapse may be altered in SZ. Briefly, several molecular factors 
contributing to presynaptic functions, including synaptic vesicle trafficking, have been found 
to be disrupted in SZ [196–199]. Similarly, altered expression of PSD proteins, such as 
PSD95 and Homer-1, and glutamate signaling pathway, as well as proteins molecules 
involved in the actin cytoskeleton has been reported in people with this disorder [148–152]. 
Emerging evidence for glial involvement in SZ indicates that all glial populations shown to 
affect synaptic functions, i.e. astrocytes, NG2 cells and microglia, contribute to the 
pathophysiology of this disorder [200–209]. Finally, ECM abnormalities in SZ have been 
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reviewed above, including evidence for altered CSPG expression in glial cells [see also 
121,210].
It is plausible to postulate that abnormalities affecting distinct elements of the tetrapartite 
synapse may be causally related, and/or interact with each and result in synaptic 
dysfunction. Although the underlying mechanisms are not yet understood, current data raises 
a number of possible hypotheses. For instance, altered CSPG expression in glial cells and 
decreased PNNs in the same subjects suggests that decreased availability of PNN molecular 
components may contribute to PNN abnormalities. ECM molecules bind to neuronal surface 
receptors (e.g. integrins), which in turn link the postsynaptic density to the actin 
cytoskeleton on one side, and to the ECM and pre-synaptic terminal of the other side. 
Through this arrangement, cell adhesion molecules (CAMs)-mediate ECM and PSD 
signaling may impact the dendritic spine actin network, and thus the spine shape [211–217]. 
This possibility is supported by evidence that several ECM molecules, including CSPGs and 
Reelin, known to modulate spine formation, size and stability through ECM receptors, are 
also implicated in the pathology of SZ [76–79, 88–92, 218]. The potential contribution of 
decreased Reelin expression to dendritic spine decreases in SZ has long been postulated 
[93,219]. As reviewed above, ECM proteases such as MMPs, secreted into the ECM by 
astrocytes and microglia in addition to neurons, have been shown to robustly affect dendritic 
spine stability [106].
5. Conclusions
We reviewed evidence that each element of the tetrapartite synapse plays a role in synaptic 
plasticity and is involved in SZ. Several glial populations, including astrocytes, NG2 cells 
and microglia have been shown to regulate synaptic functions and plasticity. Each of these 
glial cell populations has been shown to have complex, intimate relationships with the ECM. 
Several ECM molecules have been shown to have powerful effects on synaptic plasticity, 
and to be represented in ECM organized perisynaptic structures such as PNNs. Genetic and 
human postmortem evidence supports the involvement of the ECM in SZ, including loss of 
PNNs and CS-6/Glia clusters. Synaptic pathology, including loss of dendritic spines and 
molecular factors involved in spine structural stability and enriched in the PSD, is well 
established in SZ. We put forth the hypothesis that this pathology results from a disruption 
of interactions between elements of the tetrapartite synapse. Given the clinical, genetic and 
pathological heterogeneity of SZ, it is possible that synaptic pathology in specific brain 
regions may represent a point of convergence, potentially caused by a number of distinct 
molecular mechanisms in different individuals.
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ADAMS a disintegrin and matrix metalloproteases
ADAMTS ADAMS with a thrombospondin domain
AMPAR α amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor
ATP adenosine trisphosphate
C4 complement component 4
CS chondroitin sulfate
CSPG Chondroitin sulfate proteoglycan
EAAT1 excitatory amino acid transporter 1
EAAT2 excitatory amino acid transporter 2
ECM extracellular matrix
GABA γ-Aminobutyric acid
GAG glycosaminoglycan chains
GWAS genome wide association study
IHC immunocytochemistry
LTD long term depression
LTP long term potentiation
MMP matrix metalloproinase
NG2 neural/glial antigen 2
NMDA N-methyl-D-aspartate
O4 O4 sulfatide
PDGFαR platelet-derived growth factor α receptors
PNNs perineuronal nets
PSD postsynaptic density
SZ schizophrenia
WFA Wisteria floribunda agglutinin
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Fig. 1. 
Diagramatic representation of the tetrapartite synapse. Elements composing it are the pre- 
and post-synaptic terminals, astrocytic processes surrounding them and perisynaptic 
extracellular matrix condensations interposed between these elements.
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Fig. 2. 
CS-6/Glia clusters in the healthy human amygdala, immunolabeled with CS-6 antibody 
CS56. Scale bar 100 µm.
Chelini et al. Page 25
Eur Psychiatry. Author manuscript; available in PMC 2018 May 22.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Fig. 3. 
(A) Rodent CS-6 cluster (red; immunolabeled with CS56) surrounded by astrocytes (green; 
immunoreactive for glial fibrillary acidic protein (GFAP). (B) Immunolabeled CS-6/Glia 
clusters (blue) in the mouse hippocampus. These clusters are crossed by several dendrites 
arising from projection neurons (green, immunolabeled for Thy1) and are often surrounded 
by interneurons expressing parvalbumin (red). Scale bar 100 µm. (For interpretation of the 
references to colour in this figure legend, the reader is referred to the web version of this 
article.)
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